A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia

NCT01124617 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Pain
Diabetic Neuropathies
Neuralgia
Postherpetic Neuralgia

Interventions

DRUG: Tapentadol
DRUG: Placebo

Sponsor

Janssen Pharmaceutical K.K.